Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer

Wang, Zhenwei; Dai, Zhihong; Wang, Bingwei; Gao, Yuren; Gao, Xiang; Wang, Liang; Zhou, Sihai; Yang, Liqin; Qiu, Xiaoyu; Liu, Zhiyu

doi:10.2147/ott.s291267

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, olaparib has been clinically approved for the treatment of PCa, but cytotoxicity and DNA damage limit its clinical application. Z. Wang et al (58) found that the combined inhibition of c-Met and poly ADP-ribose polymerase(PARP) had a synergistic effect on blocking the growth of PCa cell lines. When the two drugs were combined, tumor invasion and migration were prominently inhibited.…”

Section: Clinical Studies Of C-met Targeting Therapy In Urologic Neop...mentioning

confidence: 99%

See 1 more Smart Citation

Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges

Zhang²,

Kang³

2023

Front. Oncol.

View full text Add to dashboard Cite

At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and drug resistance. Therefore, c-Met targeting therapy may have great potential in urologic neoplasms. Many strategies targeting c-Met have been widely used in the study of urologic neoplasms. Although the use of targeting c-Met therapy has a strong biological basis for the treatment of urologic neoplasms, the results of current clinical trials have not yielded significant results. To promote the application of c-Met targeting drugs in the clinical treatment of urologic neoplasms, it is very important to study the detailed mechanism of c-Met in urologic neoplasms and innovate c-Met targeted drugs. This paper firstly discussed the value of c-Met targeted therapy in urologic neoplasms, then summarized the related research progress, and finally explored the potential targets related to the HGF/c-Met signaling pathway. It may provide a new concept for the treatment of middle and late urologic neoplasms.

show abstract

Section: Clinical Studies Of C-met Targeting Therapy In Urologic Neop...mentioning

confidence: 99%

“…Z. Wang et al. ( 58 ) found that the combined inhibition of c-Met and poly ADP-ribose polymerase(PARP) had a synergistic effect on blocking the growth of PCa cell lines. When the two drugs were combined, tumor invasion and migration were prominently inhibited.…”

Section: Clinical Studies Of C-met Targeting Therapy In Urologic Neop...mentioning

confidence: 99%

Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges

Zhang²,

Kang³

2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…It has been reported that c-Met targeting can be used in the treatment of NSCLC, prostate cancer, gastric cancer, and other tumors [ 40 , 41 , 42 , 43 ]. New triazolo-pyridazine/pyrimidine derivatives were synthesized, evaluated, and found to inhibit c-Met kinase in A549, MCF-7, and HeLa cell lines that overexpressed c-Met.…”

Section: New Potential Heterocyclic Molecular Targeted Drugsmentioning

confidence: 99%

Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges

et al. 2023

View full text Add to dashboard Cite

Cancer is a top global public health concern. At present, molecular targeted therapy has emerged as one of the main therapies for cancer, with high efficacy and safety. The medical world continues to struggle with the development of efficient, extremely selective, and low-toxicity anticancer medications. Heterocyclic scaffolds based on the molecular structure of tumor therapeutic targets are widely used in anticancer drug design. In addition, a revolution in medicine has been brought on by the quick advancement of nanotechnology. Many nanomedicines have taken targeted cancer therapy to a new level. In this review, we highlight heterocyclic molecular-targeted drugs as well as heterocyclic-associated nanomedicines in cancer.

show abstract

“…A variety of drugs are currently being used to study whether they can enhance the efficacy of olaparib in cancer treatment. Studies have shown that abiraterone, foretinib, PHA6657, and other drugs in combination with olaparib have synergistic effects when they act on tumor cells [6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells

et al. 2022

View full text Add to dashboard Cite

Background. Bladder cancer is a common urinary system tumor. In the treatment of clinical patients, it is particularly important to find an effective treatment method to inhibit tumor growth. The world’s first PARP inhibitor olaparib is mainly used for the treatment of BRCA1/BRCA2 mutated tumors. Metformin, an antidiabetic drug, has been reported to reduce cancer incidence in humans and improve survival in cancer patients. Methods. Cell viability and proliferation were detected by CCK-8 assay and colony formation assay; cell apoptosis was detected by flow cytometry; cell migration and invasion abilities were detected by scratch assay and Transwell assay; STAT3/C-MYC signaling pathway protein were detected by western blotting. Results. Olaparib combined with metformin has better effects on the proliferation, clone formation, migration, invasion, and apoptosis of bladder cancer cells than single drug, indicating that metformin can enhance the inhibitory effect of olaparib on tumor growth and regulate the expression of STAT3/C-MYC signaling pathway proteins. Conclusion. The results of this study showed that metformin could significantly enhance the antitumor effect of olaparib on bladder cancer cells, and these effects were mediated by downregulating STAT3/C-MYC signaling pathway proteins. This finding may have potential clinical application in the treatment of bladder cancer.

show abstract

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer

Cited by 4 publications

References 22 publications

Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges

Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges

Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges

Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells

Contact Info

Product

Resources

About